Skip to main content
Top
Published in: Clinical Rheumatology 2/2022

01-02-2022 | Rheumatoid Arthritis | Original Article

Body mass index trend and variability in rheumatoid arthritis

Authors: Gregory J. Challener, Elena Myasoedova, Cynthia S. Crowson, Rachel E. Giblon, Elizabeth J. Atkinson, John M. Davis III

Published in: Clinical Rheumatology | Issue 2/2022

Login to get access

Abstract

Objective

To characterize and compare trends in body mass index (BMI) and variability in BMI between subjects with rheumatoid arthritis (RA) and matched non-RA subjects and to determine predictors of BMI trends and variability within RA subjects.

Methods

This retrospective population-based cohort study included 1114 Olmsted County, Minnesota residents, 558 with incident RA (age \(\ge\) 18 years, 1987 ACR criteria met in 1995–2009) and 556 non-RA subjects from the same underlying population with similar age, sex, and index calendar year. All subjects were followed until death, migration, or 12/31/2018. Generalized linear models with smoothing splines and random effects to account for multiple measurements per subject were used to examine trends in BMI measurements over time.

Results

Mean BMI of patients with incident RA (28.8 kg/m2) was not significantly different from that of non-RA subjects (28.9 kg/m2). There was no significant difference in BMI trends over time between RA and non-RA cohorts, or between seropositive for rheumatoid factor (RF) and/or citrullinated antibody (CCP-antibody) and seronegative RA patients, or between male and female subjects. RA subjects were noted to have significantly higher BMI variability following diagnosis compared to non-RA subjects [difference in standard deviation between RA and non-RA subjects prior to index (p = 0.12), 0–5 years after index (p = 0.044), and 5–15 years after index (p = 0.013)].

Conclusion

The BMI trajectory of the RA population is not significantly different compared to that of the non-RA population, but patients with RA demonstrate higher variability in BMI following diagnosis compared to the non-RA population.
Key Points
• This study uniquely characterizes longitudinal trajectory in BMI measures and their variability in the RA population versus the non-RA population
• This study suggests that RA patients have greater BMI variability compared to the non-RA population, which is highly relevant as BMI variability is increasingly understood as a cardiovascular risk factor
Footnotes
1
Some of the data in this manuscript was published in 2 abstracts that were in supplemental issues of a Journal associated with conference proceedings:
Challener G, Myasoedova E, Crowson CS, Giblon R, Davis JM. THU0091 Body mass index trajectory in rheumatoid arthritis [abstract]. Ann Rheum Dis 2020:79;258–9.
Challener G, Myasoedova E, Crowson C, Giblon R, Davis J. Body mass index trajectory and variability in rheumatoid arthritis [abstract]. Arthritis Rheumatol 2020;72.
 
Literature
1.
go back to reference Chooi YC, Ding C, Magkos F (2019) The epidemiology of obesity. Metabolism 92:6–10CrossRef Chooi YC, Ding C, Magkos F (2019) The epidemiology of obesity. Metabolism 92:6–10CrossRef
2.
go back to reference Feng X, Xu X, Shi Y, Liu X, Liu H, Hou H et al (2019) Body mass index and the risk of rheumatoid arthritis: an updated dose-response meta-analysis. Biomed Res Int 2019:3579081PubMedPubMedCentral Feng X, Xu X, Shi Y, Liu X, Liu H, Hou H et al (2019) Body mass index and the risk of rheumatoid arthritis: an updated dose-response meta-analysis. Biomed Res Int 2019:3579081PubMedPubMedCentral
3.
go back to reference Tedeschi SK, Cui J, Arkema EV, Robinson WH, Sokolove J, Lingampalli N et al (2017) Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: a nested case-control study of women in the Nurses’ Health Studies. Semin Arthritis Rheum 46:692–698CrossRef Tedeschi SK, Cui J, Arkema EV, Robinson WH, Sokolove J, Lingampalli N et al (2017) Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: a nested case-control study of women in the Nurses’ Health Studies. Semin Arthritis Rheum 46:692–698CrossRef
4.
go back to reference Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q et al (2015) Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther 17:86CrossRef Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q et al (2015) Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther 17:86CrossRef
5.
go back to reference Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2004) Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50:3450–3457CrossRef Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2004) Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50:3450–3457CrossRef
6.
go back to reference Escalante A, Haas RW, del Rincón I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165:1624–1629CrossRef Escalante A, Haas RW, del Rincón I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165:1624–1629CrossRef
7.
go back to reference England BR, Baker JF, Sayles H, Michaud K, Caplan L, Davis L et al (2018) Body mass index, weight loss, and cause-specific mortality in rheumatoid arthritis. Arthritis Care Res 70:11–18CrossRef England BR, Baker JF, Sayles H, Michaud K, Caplan L, Davis L et al (2018) Body mass index, weight loss, and cause-specific mortality in rheumatoid arthritis. Arthritis Care Res 70:11–18CrossRef
8.
go back to reference Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C (2017) The impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 69:157–165CrossRef Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C (2017) The impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 69:157–165CrossRef
9.
go back to reference Ajeganova S, Andersson ML, Hafström I, BARFOT Study Group (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 65:78–87CrossRef Ajeganova S, Andersson ML, Hafström I, BARFOT Study Group (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 65:78–87CrossRef
10.
go back to reference Levitsky A, Brismar K, Hafström I, Hambardzumyan K, Lourdudoss C, van Vollenhoven RF et al (2017) Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open 3:e000458CrossRef Levitsky A, Brismar K, Hafström I, Hambardzumyan K, Lourdudoss C, van Vollenhoven RF et al (2017) Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open 3:e000458CrossRef
11.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef
12.
go back to reference Myasoedova E, Davis J, Matteson EL, Crowson CS (2020) Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann Rheum Dis 79:440–444CrossRef Myasoedova E, Davis J, Matteson EL, Crowson CS (2020) Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann Rheum Dis 79:440–444CrossRef
13.
go back to reference Kremers HM, Myasoedova E, Crowson CS, Savova G, Gabriel SE, Matteson EL (2011) The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases. Rheumatology 50:6–15CrossRef Kremers HM, Myasoedova E, Crowson CS, Savova G, Gabriel SE, Matteson EL (2011) The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases. Rheumatology 50:6–15CrossRef
14.
go back to reference St Sauver JL, Grossardt BR, Yawn BP, Melton LJ, Rocca WA (2011) Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol 173:1059–1068CrossRef St Sauver JL, Grossardt BR, Yawn BP, Melton LJ, Rocca WA (2011) Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol 173:1059–1068CrossRef
15.
go back to reference Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139CrossRef Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139CrossRef
16.
go back to reference Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology 52:99–110CrossRef Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology 52:99–110CrossRef
17.
go back to reference Vlassopoulos A, Combet E, Lean ME (2014) Changing distributions of body size and adiposity with age. Int J Obes 38:857–864CrossRef Vlassopoulos A, Combet E, Lean ME (2014) Changing distributions of body size and adiposity with age. Int J Obes 38:857–864CrossRef
18.
go back to reference Jiang T, Gilthorpe MS, Shiely F, Harrington JM, Perry IJ, Kelleher CC et al (2013) Age-period-cohort analysis for trends in body mass index in Ireland. BMC Public Health 13:889CrossRef Jiang T, Gilthorpe MS, Shiely F, Harrington JM, Perry IJ, Kelleher CC et al (2013) Age-period-cohort analysis for trends in body mass index in Ireland. BMC Public Health 13:889CrossRef
19.
go back to reference Wilson R, Abbott JH (2018) Age, period and cohort effects on body mass index in New Zealand, 1997–2038. Aust N Z J Public Health 42:396–402CrossRef Wilson R, Abbott JH (2018) Age, period and cohort effects on body mass index in New Zealand, 1997–2038. Aust N Z J Public Health 42:396–402CrossRef
20.
go back to reference Seidell JC, Visscher TL (2000) Body weight and weight change and their health implications for the elderly. Eur J Clin Nutr 54:S33–S39CrossRef Seidell JC, Visscher TL (2000) Body weight and weight change and their health implications for the elderly. Eur J Clin Nutr 54:S33–S39CrossRef
21.
go back to reference Wolfe F, Michaud K (2012) Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res 64:1471–1479CrossRef Wolfe F, Michaud K (2012) Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res 64:1471–1479CrossRef
22.
go back to reference Baker JF, Cannon GW, Ibrahim S, Haroldsen C, Caplan L, Mikuls TR (2015) Predictors of longterm changes in body mass index in rheumatoid arthritis. J Rheumatol 42:920–927CrossRef Baker JF, Cannon GW, Ibrahim S, Haroldsen C, Caplan L, Mikuls TR (2015) Predictors of longterm changes in body mass index in rheumatoid arthritis. J Rheumatol 42:920–927CrossRef
23.
go back to reference Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD (2017) Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376:1332–1340CrossRef Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD (2017) Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376:1332–1340CrossRef
24.
go back to reference Oh TJ, Moon JH, Choi SH, Lim S, Park KS, Cho NH et al (2019) Body-weight fluctuation and incident diabetes mellitus, cardiovascular disease, and mortality: a 16-year prospective cohort study. J Clin Endocrinol Metab 104:639–646CrossRef Oh TJ, Moon JH, Choi SH, Lim S, Park KS, Cho NH et al (2019) Body-weight fluctuation and incident diabetes mellitus, cardiovascular disease, and mortality: a 16-year prospective cohort study. J Clin Endocrinol Metab 104:639–646CrossRef
26.
go back to reference Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732CrossRef Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732CrossRef
Metadata
Title
Body mass index trend and variability in rheumatoid arthritis
Authors
Gregory J. Challener
Elena Myasoedova
Cynthia S. Crowson
Rachel E. Giblon
Elizabeth J. Atkinson
John M. Davis III
Publication date
01-02-2022
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 2/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05919-w

Other articles of this Issue 2/2022

Clinical Rheumatology 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine